MediPharm Labs has announced it is increasing medical cannabis exports to Australia.
The cannabis extraction and cannabinoid isolation company has completed its second set of export shipments of medical cannabis concentrate, which was 137% greater in volume compared to its first export to Australia in June 2019.
The firm received its second set of export permits from Health Canada to ship an increased volume of medical cannabis concentrates from Canada to Australia.
Prior to the shipment, the Australian government’s Office of Drug Control Section also issued a second set of import permits.
“We are pleased to have completed our second set of shipments of medical cannabis concentrate into Australia in the third quarter as we look to participate in addressing the growing Australian medical patient demand,” said Pat McCutcheon, chief executive officer.
“As international demand for purified cannabis concentrates continues to grow, we have focused on expanding our global supply chain and our international presence, including through our recently announced supply agreement for the German medical market.
“We have also focused on meeting diverse international regulatory and permitting requirements, including working towards our EU GMP, to grow export volumes of MediPharm Labs’ private-label concentrates.”
Founded in 2015, MediPharm Labs specialises in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products.
Last week, an Australian territory became the first in the nation to legalise recreational cannabis use.
Politicians in the Australian Capital Territory, which includes the capital city of Canberra, passed a bill allowing adults to possess up to 50 grams of the drug.
Users will also be allowed to grow four plants at home under the legislation, which comes into effect in January.
